Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Abstract Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula). Notably, neovascular, or wet, AMD (nAMD) occurs when new, abnormal blood vessels grow under the mac...

Full description

Bibliographic Details
Main Authors: Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Health Services Research
Subjects:
Brolucizumab
Neovascular age-related macular degeneration
nAMD
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12913-022-07972-w

Similar Items

Similar Items